A year of advancing novel regenerative biotherapeutics toward patient care

Mayo Clinic's Center for Regenerative Biotherapeutics has advanced the development and biomanufacturing of novel therapeutics, called biologics, for cancer and inflammatory conditions into clinical trials. "My dream has been to develop innovative technologies that go beyond treating symptoms to curing diseases. The ultimate aim is to ensure that these advancements are accessible to all patients in need," says Julie Allickson, Ph.D., the Michael S. and Mary Sue Shannon Director of the Mayo Clinic Center for Regenerative Biotherapeutics. Dr.…
Source: Mayo Clinic Research News - Category: Research Source Type: news